With the pandemic in the rearview mirror, Wall Street has mixed views on the prospects of COVID-19 vaccine makers, as the group, once the favorite among investors, is grappling with a steep decline in sales amid falling infections. The FDA-Authorized COVID-19 makers in the U.S., Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), and Novavax (NASDAQ:NVAX), have … Read more
European Union regulators warned that frequent Covid-19 booster shots could adversely affect the immune system and may not be feasible. Repeat booster doses every four months could eventually weaken the immune system and tire out people, according to the European Medicines Agency. Instead, countries should leave more time between booster programs and tie them to … Read more
Moderna and BioNTech plunged more than 16% on Monday amid a critical tweet from Senator Bernie Sanders. Sanders highlighted the surge in the companies’ stock prices after the Omicron variant was identified. “It’s time for these pharmaceutical companies to share their vaccines with the world and start controlling their greed,” Sanders tweeted. Shares of COVID-19 … Read more
The ₹7,500 crore pharma major is one of the firms that has tied up with Russian Direct Investment Fund to manufacture COVID-19 vaccine Sputnik V in India. The Income Tax Department has detected “unaccounted” income of ₹550 crore and has seized over ₹142 crore cash after it recently raided Hyderabad-based Hetero pharmaceutical group, official sources … Read more
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adultage groups in Phase 2 trial Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups High immune response after a single dose in patients with prior infection shows strong booster potential Global Phase 3 study expected to … Read more
American depositary shares of Vaccitech fell nearly 20% in their Nasdaq debut on Friday, giving the co-inventor of the Covid-19 vaccine developed by AstraZeneca Plc and Oxford University a market value of about $464 million. The biotech firm’s shares opened at $13.62, below the initial public offering (IPO) price of $17 apiece for 6.5 million … Read more
The head of the world’s biggest vaccine maker and the World Health Organization’s chief scientist said manufacturers of coronavirus shots face a global shortage of the raw materials needed to churn out the inoculations. Adar Poonawalla, the chief executive officer of the Serum Institute of India Ltd. — which is licensed to produce hundreds of … Read more